摘要
目的探讨新辅助放化疗对直肠癌患者临床分期、手术方式及预后的影响。方法选取行直肠癌诊治的124例作为研究对象,根据治疗方式不同将其分为实验组和对照组,实验组行新辅助放化疗和手术治疗,共53例,对照组则直接行手术治疗,共71例。分析实验组新辅助放化疗后患者的治疗效果、临床分期变化情况及不良反应情况;分析两组患者的手术切除率、保肛率、术后并发症及预后(生活质量及生存情况)。结果实验组经新辅助放化疗后其临床分期由Ⅱ期(34例)和Ⅲ期(19例)变为Ⅰ期(24例)、Ⅱ期(25例)和Ⅲ期(4例);实验组经新辅助放化疗后,不良反应发生率为26. 42%,经对症处理后均顺利完成后续手术治疗;实验组切除率及保肛率(100. 00%,96. 23%)均高于对照组(92. 96%,67. 61%),且具有统计学意义(P <0. 05);实验组术后并发症总发生率为24. 53%,对照组术后并发症总发生率为28. 17%,两组差异无统计学意义(P> 0. 05);实验组术后生活质量高于对照组,且差异均具有统计学意义(P <0. 05);实验组2年生存率(62. 26%)略高于对照组(40. 85%),两组差异无统计学意义(P> 0. 05)。结论新辅助放化疗可降低直肠癌患者临床分期,从而提高其手术切除率及保肛率,改善生活质量,延长寿命。
Objective To explore the effect of neoadjuvant chemoradiotherapy on clinical stage,operation mode and prognosis of patients with rectal cancer.Methods 124 cases of rectal cancer who were diagnosed and treated in our hospital were selected as the subjects from February 2012 to January 2015,they were divided into experimental group and control group according to different treatment methods,the experimental groups were given neoadjuvant chemoradiotherapy and surgical treatment which was 53,while the control group was given direct surgical treatment which was 71.the treatment effect,the clinical stages and adverse reactions of the patients in the experimental group after neoadjuvant chemoradiotherapy were analyzed;the surgical resection rate,sphincter preservation,postoperative complications and prognosis(quality of life and survival)were collected and analyzed in the two groups.Results The clinical stages of the experimental group were changed from stageⅡ(34 cases)and stageⅢ(19 cases)to stage I(24 cases),stageⅡ(25 cases)and stageⅢ(4 cases)after neoadjuvant radiotherapy;the adverse reaction rate of the experimental group was 26.42%after the neoadjuvant chemotherapy and radiotherapy,and they successfully completed the follow-up surgical treatment after symptomatic treatment;the resection rate and sphincter preservation rate in the experimental group(100%,96.23%)were higher than those in the control group(92.96%,67.61%),and the difference was statistically significant(P<0.05);the total incidence of postoperative complications of two groups were 24.53%and 28.17%,and there was no significant difference between the two groups(P>0.05);the quality of life in the experimental group was higher than that in the control group,and the difference was statistically significant(P<0.05);the 2 year survival rate of the experimental group(62.26%)was slightly higher than that of the control group(40.85%),and there was no significant difference between the two groups(P>0.05).Conclusion Neoadjuvant chemoradiotherapy can reduce th
作者
权瑞泉
熊明兰
QUAN Ruiquan;XIONG Minglan(Dongfeng Hospital of Hubei Medical College,Shiyan,442008)
出处
《实用癌症杂志》
2018年第12期2037-2040,共4页
The Practical Journal of Cancer
关键词
直肠癌
新辅助放化疗
临床分期
保肛率
预后
Rectal cancer
Neoadjuvant chemoradiotherapy
Clinical stage
Sphincter preservation rate
Prognosis
